Gene transfer to human joints

Progress toward a gene therapy of arthritis

Christopher H Evans, Paul D. Robbins, Steven C. Ghivizzani, Mary Chester Wasko, Matthew M. Tomaino, Richard Kang, Thomas A. Muzzonigro, Molly Vogt, Elaine M. Elder, Theresa L. Whiteside, Simon C. Watkins, James H. Herndon

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

This article describes the clinical application of gene therapy to a nonlethal disease, rheumatoid arthritis (RA). Intraarticular transfer of IL-1 receptor antagonist (IL-1Ra) cDNA reduces disease in animal models of RA. Whether this procedure is safe and feasible in humans was addressed in a phase I clinical study involving nine postmenopausal women with advanced RA who required unilateral sialastic implant arthroplasty of the 2nd-5th metacarpophalangeal (MCP) joints. Cultures of autologous synovial fibroblasts were established and divided into two. One was transduced with a retrovirus carrying IL-1Ra cDNA; the other provided untransduced, control cells. In a dose escalation, double-blinded fashion, two MCP joints were injected with transduced cells, and two MCP joints received control cells. One week later, injected joints were resected and examined for evidence of successful gene transfer and expression by using RT-PCR, ex vivo production of IL-1Ra, in situ hybridization, and immunohistochemistry. All subjects tolerated the protocol well, without adverse events. Unlike control joints, those receiving transduced cells gave positive RT-PCR signals. Synovia that were recovered from the MCP joints of intermediate and high dose subjects produced elevated amounts of IL-1Ra (P = 0.01). Clusters of cells expressing high levels of IL-1Ra were present on synovia of transduced joints. No adverse events occurred. Thus, it is possible to transfer a potentially therapeutic gene safely to human rheumatoid joints and to obtain intraarticular, transgene expression. This conclusion justifies additional efficacy studies and encourages further development of genetic approaches to the treatment of arthritis and related disorders.

Original languageEnglish (US)
Pages (from-to)8698-8703
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume102
Issue number24
DOIs
StatePublished - Jun 14 2005
Externally publishedYes

Fingerprint

Interleukin-1 Receptors
Metacarpophalangeal Joint
Genetic Therapy
Arthritis
Joints
Rheumatoid Arthritis
Genes
Synovial Fluid
Complementary DNA
Animal Disease Models
Polymerase Chain Reaction
Retroviridae
Transgenes
Arthroplasty
In Situ Hybridization
Fibroblasts
Immunohistochemistry
Gene Expression
Therapeutics

Keywords

  • Clinical trial
  • Interleukin-1 receptor antagonist
  • Retrovirus
  • Synovium

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Gene transfer to human joints : Progress toward a gene therapy of arthritis. / Evans, Christopher H; Robbins, Paul D.; Ghivizzani, Steven C.; Wasko, Mary Chester; Tomaino, Matthew M.; Kang, Richard; Muzzonigro, Thomas A.; Vogt, Molly; Elder, Elaine M.; Whiteside, Theresa L.; Watkins, Simon C.; Herndon, James H.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, No. 24, 14.06.2005, p. 8698-8703.

Research output: Contribution to journalArticle

Evans, CH, Robbins, PD, Ghivizzani, SC, Wasko, MC, Tomaino, MM, Kang, R, Muzzonigro, TA, Vogt, M, Elder, EM, Whiteside, TL, Watkins, SC & Herndon, JH 2005, 'Gene transfer to human joints: Progress toward a gene therapy of arthritis', Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 24, pp. 8698-8703. https://doi.org/10.1073/pnas.0502854102
Evans, Christopher H ; Robbins, Paul D. ; Ghivizzani, Steven C. ; Wasko, Mary Chester ; Tomaino, Matthew M. ; Kang, Richard ; Muzzonigro, Thomas A. ; Vogt, Molly ; Elder, Elaine M. ; Whiteside, Theresa L. ; Watkins, Simon C. ; Herndon, James H. / Gene transfer to human joints : Progress toward a gene therapy of arthritis. In: Proceedings of the National Academy of Sciences of the United States of America. 2005 ; Vol. 102, No. 24. pp. 8698-8703.
@article{01e3fb1ea574423281bcc51d3c9c3fd5,
title = "Gene transfer to human joints: Progress toward a gene therapy of arthritis",
abstract = "This article describes the clinical application of gene therapy to a nonlethal disease, rheumatoid arthritis (RA). Intraarticular transfer of IL-1 receptor antagonist (IL-1Ra) cDNA reduces disease in animal models of RA. Whether this procedure is safe and feasible in humans was addressed in a phase I clinical study involving nine postmenopausal women with advanced RA who required unilateral sialastic implant arthroplasty of the 2nd-5th metacarpophalangeal (MCP) joints. Cultures of autologous synovial fibroblasts were established and divided into two. One was transduced with a retrovirus carrying IL-1Ra cDNA; the other provided untransduced, control cells. In a dose escalation, double-blinded fashion, two MCP joints were injected with transduced cells, and two MCP joints received control cells. One week later, injected joints were resected and examined for evidence of successful gene transfer and expression by using RT-PCR, ex vivo production of IL-1Ra, in situ hybridization, and immunohistochemistry. All subjects tolerated the protocol well, without adverse events. Unlike control joints, those receiving transduced cells gave positive RT-PCR signals. Synovia that were recovered from the MCP joints of intermediate and high dose subjects produced elevated amounts of IL-1Ra (P = 0.01). Clusters of cells expressing high levels of IL-1Ra were present on synovia of transduced joints. No adverse events occurred. Thus, it is possible to transfer a potentially therapeutic gene safely to human rheumatoid joints and to obtain intraarticular, transgene expression. This conclusion justifies additional efficacy studies and encourages further development of genetic approaches to the treatment of arthritis and related disorders.",
keywords = "Clinical trial, Interleukin-1 receptor antagonist, Retrovirus, Synovium",
author = "Evans, {Christopher H} and Robbins, {Paul D.} and Ghivizzani, {Steven C.} and Wasko, {Mary Chester} and Tomaino, {Matthew M.} and Richard Kang and Muzzonigro, {Thomas A.} and Molly Vogt and Elder, {Elaine M.} and Whiteside, {Theresa L.} and Watkins, {Simon C.} and Herndon, {James H.}",
year = "2005",
month = "6",
day = "14",
doi = "10.1073/pnas.0502854102",
language = "English (US)",
volume = "102",
pages = "8698--8703",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "24",

}

TY - JOUR

T1 - Gene transfer to human joints

T2 - Progress toward a gene therapy of arthritis

AU - Evans, Christopher H

AU - Robbins, Paul D.

AU - Ghivizzani, Steven C.

AU - Wasko, Mary Chester

AU - Tomaino, Matthew M.

AU - Kang, Richard

AU - Muzzonigro, Thomas A.

AU - Vogt, Molly

AU - Elder, Elaine M.

AU - Whiteside, Theresa L.

AU - Watkins, Simon C.

AU - Herndon, James H.

PY - 2005/6/14

Y1 - 2005/6/14

N2 - This article describes the clinical application of gene therapy to a nonlethal disease, rheumatoid arthritis (RA). Intraarticular transfer of IL-1 receptor antagonist (IL-1Ra) cDNA reduces disease in animal models of RA. Whether this procedure is safe and feasible in humans was addressed in a phase I clinical study involving nine postmenopausal women with advanced RA who required unilateral sialastic implant arthroplasty of the 2nd-5th metacarpophalangeal (MCP) joints. Cultures of autologous synovial fibroblasts were established and divided into two. One was transduced with a retrovirus carrying IL-1Ra cDNA; the other provided untransduced, control cells. In a dose escalation, double-blinded fashion, two MCP joints were injected with transduced cells, and two MCP joints received control cells. One week later, injected joints were resected and examined for evidence of successful gene transfer and expression by using RT-PCR, ex vivo production of IL-1Ra, in situ hybridization, and immunohistochemistry. All subjects tolerated the protocol well, without adverse events. Unlike control joints, those receiving transduced cells gave positive RT-PCR signals. Synovia that were recovered from the MCP joints of intermediate and high dose subjects produced elevated amounts of IL-1Ra (P = 0.01). Clusters of cells expressing high levels of IL-1Ra were present on synovia of transduced joints. No adverse events occurred. Thus, it is possible to transfer a potentially therapeutic gene safely to human rheumatoid joints and to obtain intraarticular, transgene expression. This conclusion justifies additional efficacy studies and encourages further development of genetic approaches to the treatment of arthritis and related disorders.

AB - This article describes the clinical application of gene therapy to a nonlethal disease, rheumatoid arthritis (RA). Intraarticular transfer of IL-1 receptor antagonist (IL-1Ra) cDNA reduces disease in animal models of RA. Whether this procedure is safe and feasible in humans was addressed in a phase I clinical study involving nine postmenopausal women with advanced RA who required unilateral sialastic implant arthroplasty of the 2nd-5th metacarpophalangeal (MCP) joints. Cultures of autologous synovial fibroblasts were established and divided into two. One was transduced with a retrovirus carrying IL-1Ra cDNA; the other provided untransduced, control cells. In a dose escalation, double-blinded fashion, two MCP joints were injected with transduced cells, and two MCP joints received control cells. One week later, injected joints were resected and examined for evidence of successful gene transfer and expression by using RT-PCR, ex vivo production of IL-1Ra, in situ hybridization, and immunohistochemistry. All subjects tolerated the protocol well, without adverse events. Unlike control joints, those receiving transduced cells gave positive RT-PCR signals. Synovia that were recovered from the MCP joints of intermediate and high dose subjects produced elevated amounts of IL-1Ra (P = 0.01). Clusters of cells expressing high levels of IL-1Ra were present on synovia of transduced joints. No adverse events occurred. Thus, it is possible to transfer a potentially therapeutic gene safely to human rheumatoid joints and to obtain intraarticular, transgene expression. This conclusion justifies additional efficacy studies and encourages further development of genetic approaches to the treatment of arthritis and related disorders.

KW - Clinical trial

KW - Interleukin-1 receptor antagonist

KW - Retrovirus

KW - Synovium

UR - http://www.scopus.com/inward/record.url?scp=20844432900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844432900&partnerID=8YFLogxK

U2 - 10.1073/pnas.0502854102

DO - 10.1073/pnas.0502854102

M3 - Article

VL - 102

SP - 8698

EP - 8703

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 24

ER -